BioSpace News Archive

The Global Acute Myeloid Leukemia Therapeutics Market is forecast to reach USD 3.56 Billion by 2027, according to a new report by Reports and Data.

Sequana Medical NV, a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company.

Closing on € 30 million, AstriVax has raised the largest amount of seed capital in the history of KU Leuven spin-offs.

AlzeCure Pharma AB announced that its interim report for the period January - June 2022 is now available on the company’s website.

Bionomics is a clinical stage biopharmaceutical company developing novel, allosteric, ion channel modulators designed to transform the lives of patients suffering from serious CNS disorders with high unmet medical need.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced positive data from a global Phase 2/3 trial evaluating Clover’s COVID-19 vaccine candidate, SCB-2019, in adolescents.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst’s antiviral influenza therapy, RAPIVAB® (peramivir injection), for approximately $7 million.

Immuneering Corporation announced that management will participate in two September investor conferences to share commentary around the Company’s pipeline, platform, and business strategy.

Todos Medical, Ltd. today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory Provista Diagnostics, Inc. has enrolled a female Long COVID who was unable to secure MonkeyPox testing while severely symptomatic into diagnostic case study series.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced results from the ULTIMATE I & II Phase 3 trials evaluating ublituximab, the Company’s investigational anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis (RMS), were published in The New England Journal of Medicine (NEJM).